VivoSeq
Other

Montelukast

0

Pipeline Programs

3

Active Trials

5

Companies Involved

Montelukast is an early-stage landscape with 0 programs across 5 companies. The most active players are Torrent Pharmaceuticals Limited, GSK, Qilu Pharmaceutical Co., Ltd..

Pipeline Metrics

Competitive Density

14/100

Pipeline Velocity

6/100

Mech. Concentration

N/A

Completion Rate

96/100

Attrition Rate

2/100

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Programs by Phase

No pipeline programs currently tracked for this disease.

Trial Status

52

clinical trials

Completed43 · 83%
Unknown status4 · 8%
Recruiting2 · 4%
Not yet recruiting1 · 2%
Suspended1 · 2%
Withdrawn1 · 2%

Trial Activity

52 trials

Efficacy of Montelukast on STEMl Patients
Recruiting·SShanghai Zhongshan Hospital·Phase 3·NCT07320625·512 enrolled
Lipid Mediators & Cancer: Montelukast, SPM, and Almonds
Not yet recruiting·UUniversity of South Florida·Phase 1·NCT06887673·56 enrolled
Montelukast in Exercise-Induced Bronchospasm - 2003 (0476-270)
Completed··Phase 3·NCT00092131·51 enrolled
Bioequivalence Study of Montelukast 5 mg Chewable
Completed·GSK logoGSK·Phase 1·NCT01863654·32 enrolled
Bioequivalence Study of Montelukast 10 mg Tablets
Completed·GSK logoGSK·Phase 1·NCT01943942·32 enrolled
Page 1 of 4

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)